 "Govt needs to invest $5bn a year for next 5 years in biotech: PwC")
Ahead of the Budget, global consultancy firm PwC says government needs to invest up to $5 billion (around Rs 30,000 crore) each year for the next five years to enable biotech sector to become a $100 billion industry by 2025.
As part of the wish-list for the pharmaceutical sector in the upcoming Budget, the consultancy firm has also asked the government to allocate Rs 500 crore each year from the R&D cess accessible by the Technology Development Board to stimulate the biotech sector.
"Make bio-manufacturing the next big opportunity after generics for India. Invest $4-5 billion each year in the next five years to grow the biotech industry to $100 billion by 2025," PwC India leader pharma & life sciences Sujay Shetty said in a statement.
The consultancy firm also proposed to the government to eliminate service tax for the domestic contract research organisations (CRO).
"Service tax for the CRO industry is putting Indian companies at a significant disadvantage over some of our neighbors and competitors. We request elimination or substantial reduction in the service tax, especially for overseas clients paying in foreign currency," Shetty said.
Further, the consultancy firm asked the government to encourage setting up of venture capital funds focused on investments in biotechnology.
"...All contributions by Indian corporate including pharma companies to SEBI registered biotechnology funds should be eligible for the weighted average tax deduction," Shetty said.
The consultancy firm also proposed to the government to give a tax holiday for a period of ten year for indigenously developed biopharma drugs.
Further, companies must be encouraged to start their manufacturing operations in India, it added.
"The current duty and tax structure acts as a deterrent for local manufacturing as customs duty on complete system is lower than the components for manufacturing and in addition the buyers have to spend additional central excise duty and sales tax on locally manufactured goods making it prohibitively expensive compared to imports," Shetty said.
The consultancy firm also asked the government to give 100 per cent exemption of excise/customs duty on all life saving medicines including anti-cancer and anti-AIDS drugs.
It further proposed to the government to hike FDI in health insurance companies to 49 per cent.
As part of the wish-list for the pharmaceutical sector in the upcoming Budget, the consultancy firm has also asked the government to allocate Rs 500 crore each year from the R&D cess accessible by the Technology Development Board to stimulate the biotech sector.
"Make bio-manufacturing the next big opportunity after generics for India. Invest $4-5 billion each year in the next five years to grow the biotech industry to $100 billion by 2025," PwC India leader pharma & life sciences Sujay Shetty said in a statement.
The consultancy firm also proposed to the government to eliminate service tax for the domestic contract research organisations (CRO).
"Service tax for the CRO industry is putting Indian companies at a significant disadvantage over some of our neighbors and competitors. We request elimination or substantial reduction in the service tax, especially for overseas clients paying in foreign currency," Shetty said.
Further, the consultancy firm asked the government to encourage setting up of venture capital funds focused on investments in biotechnology.
"...All contributions by Indian corporate including pharma companies to SEBI registered biotechnology funds should be eligible for the weighted average tax deduction," Shetty said.
The consultancy firm also proposed to the government to give a tax holiday for a period of ten year for indigenously developed biopharma drugs.
Further, companies must be encouraged to start their manufacturing operations in India, it added.
"The current duty and tax structure acts as a deterrent for local manufacturing as customs duty on complete system is lower than the components for manufacturing and in addition the buyers have to spend additional central excise duty and sales tax on locally manufactured goods making it prohibitively expensive compared to imports," Shetty said.
The consultancy firm also asked the government to give 100 per cent exemption of excise/customs duty on all life saving medicines including anti-cancer and anti-AIDS drugs.
It further proposed to the government to hike FDI in health insurance companies to 49 per cent.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%